Percutaneous	B:C3854551
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	O
for	O
symptomatic	O
uterine	I:C0341858
adenomyosis	I:C0341858
:	O
initial	O
experience	I:C0596545

Percutaneous	O
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	B:C0003962
for	O
symptomatic	O
uterine	I:C0341858
adenomyosis	I:C0341858
:	O
initial	O
experience	I:C0596545

Percutaneous	O
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	O
for	O
symptomatic	B:C0341858
uterine	I:C0341858
adenomyosis	I:C0341858
:	O
initial	O
experience	I:C0596545

Percutaneous	O
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	O
for	O
symptomatic	O
uterine	I:C0341858
adenomyosis	I:C0341858
:	O
initial	B:C0596545
experience	I:C0596545

To	O
evaluate	B:C0220825
the	O
feasibility	O
,	O
safety	O
and	O
technical	O
efficacy	O
of	O
ultrasound	O
-	I:C3854551
guided	I:C3854551
percutaneous	I:C3854551
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	O
for	O
adenomyosis	O
.	O

To	O
evaluate	O
the	O
feasibility	B:C0015730
,	O
safety	O
and	O
technical	O
efficacy	O
of	O
ultrasound	O
-	I:C3854551
guided	I:C3854551
percutaneous	I:C3854551
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	O
for	O
adenomyosis	O
.	O

To	O
evaluate	O
the	O
feasibility	O
,	O
safety	O
and	O
technical	O
efficacy	O
of	O
ultrasound	B:C3854551
-	I:C3854551
guided	I:C3854551
percutaneous	I:C3854551
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	O
for	O
adenomyosis	O
.	O

To	O
evaluate	O
the	O
feasibility	O
,	O
safety	O
and	O
technical	O
efficacy	O
of	O
ultrasound	O
-	I:C3854551
guided	I:C3854551
percutaneous	I:C3854551
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	B:C0003962
for	O
adenomyosis	O
.	O

To	O
evaluate	O
the	O
feasibility	O
,	O
safety	O
and	O
technical	O
efficacy	O
of	O
ultrasound	O
-	I:C3854551
guided	I:C3854551
percutaneous	I:C3854551
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	O
for	O
adenomyosis	B:C0341858
.	O

Between	O
May	O
2015	O
and	O
May	O
2016	O
,	O
a	O
total	O
of	O
25	O
patients	O
with	O
symptomatic	B:C0341858
adenomyosis	I:C0341858
who	O
underwent	O
ultrasound	O
-	I:C3854551
guided	I:C3854551
percutaneous	I:C3854551
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	O
were	O
included	O
in	O
this	O
retrospective	O
study	I:C0035363
.	O

Between	O
May	O
2015	O
and	O
May	O
2016	O
,	O
a	O
total	O
of	O
25	O
patients	O
with	O
symptomatic	O
adenomyosis	I:C0341858
who	O
underwent	O
ultrasound	B:C3854551
-	I:C3854551
guided	I:C3854551
percutaneous	I:C3854551
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	O
were	O
included	O
in	O
this	O
retrospective	O
study	I:C0035363
.	O

Between	O
May	O
2015	O
and	O
May	O
2016	O
,	O
a	O
total	O
of	O
25	O
patients	O
with	O
symptomatic	O
adenomyosis	I:C0341858
who	O
underwent	O
ultrasound	O
-	I:C3854551
guided	I:C3854551
percutaneous	I:C3854551
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	B:C0003962
were	O
included	O
in	O
this	O
retrospective	O
study	I:C0035363
.	O

Between	O
May	O
2015	O
and	O
May	O
2016	O
,	O
a	O
total	O
of	O
25	O
patients	O
with	O
symptomatic	O
adenomyosis	I:C0341858
who	O
underwent	O
ultrasound	O
-	I:C3854551
guided	I:C3854551
percutaneous	I:C3854551
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	O
were	O
included	O
in	O
this	O
retrospective	B:C0035363
study	I:C0035363
.	O

A	O
matching	B:C0150103
cohort	O
of	O
50	O
patients	O
underwent	O
ultrasound	O
-	I:C3854551
guided	I:C3854551
percutaneous	I:C3854551
microwave	I:C3854551
ablation	I:C3854551
without	O
artificial	O
ascites	O
as	O
controls	O
.	O

A	O
matching	O
cohort	B:C0599755
of	O
50	O
patients	O
underwent	O
ultrasound	O
-	I:C3854551
guided	I:C3854551
percutaneous	I:C3854551
microwave	I:C3854551
ablation	I:C3854551
without	O
artificial	O
ascites	O
as	O
controls	O
.	O

A	O
matching	O
cohort	O
of	O
50	O
patients	O
underwent	O
ultrasound	B:C3854551
-	I:C3854551
guided	I:C3854551
percutaneous	I:C3854551
microwave	I:C3854551
ablation	I:C3854551
without	O
artificial	O
ascites	O
as	O
controls	O
.	O

A	O
matching	O
cohort	O
of	O
50	O
patients	O
underwent	O
ultrasound	O
-	I:C3854551
guided	I:C3854551
percutaneous	I:C3854551
microwave	I:C3854551
ablation	I:C3854551
without	O
artificial	O
ascites	B:C0003962
as	O
controls	O
.	O

Artificial	O
ascites	B:C0003962
was	O
successfully	O
achieved	O
in	O
all	O
of	O
the	O
25	O
patients	O
with	O
the	O
administration	O
of	O
a	O
median	O
of	O
550	O
mL	O
(	O
range	O
,	O
250	O
-	O
1200	O
mL	O
)	O
of	O
solution	O
.	O

Artificial	O
ascites	O
was	O
successfully	O
achieved	B:C0243095
in	O
all	O
of	O
the	O
25	O
patients	O
with	O
the	O
administration	O
of	O
a	O
median	O
of	O
550	O
mL	O
(	O
range	O
,	O
250	O
-	O
1200	O
mL	O
)	O
of	O
solution	O
.	O

Artificial	O
ascites	O
was	O
successfully	O
achieved	O
in	O
all	O
of	O
the	O
25	O
patients	O
with	O
the	O
administration	B:C1533734
of	O
a	O
median	O
of	O
550	O
mL	O
(	O
range	O
,	O
250	O
-	O
1200	O
mL	O
)	O
of	O
solution	O
.	O

Artificial	O
ascites	O
was	O
successfully	O
achieved	O
in	O
all	O
of	O
the	O
25	O
patients	O
with	O
the	O
administration	O
of	O
a	O
median	B:C0549183
of	O
550	O
mL	O
(	O
range	O
,	O
250	O
-	O
1200	O
mL	O
)	O
of	O
solution	O
.	O

Artificial	O
ascites	O
was	O
successfully	O
achieved	O
in	O
all	O
of	O
the	O
25	O
patients	O
with	O
the	O
administration	O
of	O
a	O
median	O
of	O
550	O
mL	O
(	O
range	O
,	O
250	O
-	O
1200	O
mL	O
)	O
of	O
solution	B:C0525069
.	O

There	O
was	O
substantial	O
improvement	O
in	O
achieving	B:C0243095
a	O
better	O
antenna	O
path	O
in	O
100	O
%	O
(	O
20/20	O
)	O
of	O
the	O
cases	O
with	O
a	O
poor	O
antenna	O
path	O
.	O

The	O
complete	O
separation	O
was	O
achieved	B:C0243095
in	O
23	O
of	O
25	O
patients	O
.	O

The	O
mean	O
ablation	O
time	O
was	O
26.5	O
±	O
7.3	O
min	O
and	O
the	O
median	B:C0549183
non-perfusion	O
volume	O
ratio	O
was	O
76	O
%	O
which	O
was	O
similar	O
to	O
the	O
control	O
group	O
(	O
p	O
>	O
.05	O
)	O
.	O

Patient	B:C0582148
pain	I:C0582148
scores	I:C0582148
for	O
dysmenorrhoea	O
showed	O
a	O
statistically	O
significant	O
decline	O
from	O
the	O
baseline	O
of	O
6.71	O
±	O
0.96	O
to	O
2.92	O
±	O
0.79	O
and	O
the	O
symptom	O
severity	O
score	O
declined	O
statistically	O
significantly	O
from	O
21.8	O
±	O
5.5	O
to	O
16.4	O
±	O
4.8	O
at	O
3	O
months	O
follow	O
-	O
up	O
.	O

Patient	O
pain	I:C0582148
scores	I:C0582148
for	O
dysmenorrhoea	B:C0013390
showed	O
a	O
statistically	O
significant	O
decline	O
from	O
the	O
baseline	O
of	O
6.71	O
±	O
0.96	O
to	O
2.92	O
±	O
0.79	O
and	O
the	O
symptom	O
severity	O
score	O
declined	O
statistically	O
significantly	O
from	O
21.8	O
±	O
5.5	O
to	O
16.4	O
±	O
4.8	O
at	O
3	O
months	O
follow	O
-	O
up	O
.	O

Percutaneous	B:C3854551
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	O
is	O
feasible	O
,	O
safe	O
and	O
can	O
be	O
effective	O
in	O
improving	O
access	O
for	O
treatment	O
of	O
adenomyosis	O
.	O

Percutaneous	O
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	B:C0003962
is	O
feasible	O
,	O
safe	O
and	O
can	O
be	O
effective	O
in	O
improving	O
access	O
for	O
treatment	O
of	O
adenomyosis	O
.	O

Percutaneous	O
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	O
is	O
feasible	O
,	O
safe	B:C3266157
and	O
can	O
be	O
effective	O
in	O
improving	O
access	O
for	O
treatment	O
of	O
adenomyosis	O
.	O

Percutaneous	O
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	O
is	O
feasible	O
,	O
safe	O
and	O
can	O
be	O
effective	O
in	O
improving	O
access	B:C0444454
for	O
treatment	O
of	O
adenomyosis	O
.	O

Percutaneous	O
microwave	I:C3854551
ablation	I:C3854551
with	O
artificial	O
ascites	O
is	O
feasible	O
,	O
safe	O
and	O
can	O
be	O
effective	O
in	O
improving	O
access	O
for	O
treatment	O
of	O
adenomyosis	B:C0341858
.	O

